Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC.
Thomas BergerB BrochetL BrambillaPaul S GiacominiX MontalbánA Vasco SalgadoR SuA BretagnePublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
At 12 months after versus 12 months before DMF initiation, ARR was significantly lower, the majority of patients were relapse-free, and multiple PRO measures showed improvement (overall and for subgroups), suggesting that DMF is effective based on clinical outcomes and from a patient perspective.Clinical trial: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC), NCT01930708, https://clinicaltrials.gov/ct2/show/NCT01930708.
Keyphrases
- patient reported outcomes
- multiple sclerosis
- disease activity
- clinical trial
- rheumatoid arthritis
- systemic lupus erythematosus
- white matter
- randomized controlled trial
- systematic review
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- computed tomography
- ejection fraction
- chronic kidney disease
- case report
- study protocol
- newly diagnosed
- mass spectrometry
- prognostic factors
- ms ms
- phase ii
- image quality
- positron emission tomography